{
    "clinical_study": {
        "@rank": "47118", 
        "brief_summary": {
            "textblock": "To study the safety, tolerance, and pharmacokinetics of a single dose of bis-POM PMEA\n      (adefovir dipivoxil) when administered by the oral route in patients with HIV infection."
        }, 
        "brief_title": "Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Five patients are entered at each of three dose levels of bis-POM PMEA administered orally\n      in a single dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  AZT, ddI, or ddC (provided patient has been on a stable regimen for at least 4 weeks\n             prior to study entry).\n\n          -  Prophylactic aerosolized pentamidine, fluconazole, ketoconazole,\n             trimethoprim/sulfamethoxazole, or dapsone (provided patient has been on a stable\n             regimen for at least 4 weeks prior to study entry).\n\n        Patients must have:\n\n          -  Documented HIV infection or diagnosis of AIDS.\n\n          -  Life expectancy of at least 3 months.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior AZT, ddI, or ddC.\n\n          -  Prophylactic aerosolized pentamidine, fluconazole, ketoconazole,\n             trimethoprim/sulfamethoxazole, or dapsone.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Active, serious infections (other than HIV infections) that require parenteral\n             antibiotic therapy.\n\n          -  Clinically significant cardiac disease, including symptoms of ischemia, congestive\n             heart failure, or arrhythmia.\n\n          -  Gastrointestinal malabsorption syndrome or inability to receive oral medication.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Diuretics.\n\n          -  Amphotericin B.\n\n          -  Aminoglycoside antibiotics.\n\n          -  Parenteral antibiotics.\n\n          -  Other nephrotoxic agents.\n\n          -  Other investigational agents.\n\n          -  Non-steroidal anti-inflammatory drugs.\n\n          -  Aspirin.\n\n        Prior Medication:\n\n        Excluded within 2 weeks prior to study entry:\n\n          -  Diuretics.\n\n          -  Amphotericin B.\n\n          -  Aminoglycoside antibiotics.\n\n          -  Parenteral antibiotics.\n\n          -  Other nephrotoxic agents.\n\n          -  Other investigational agents.\n\n        Excluded within 3 days prior to study entry:\n\n          -  Non-steroidal anti-inflammatory drugs.\n\n          -  Aspirin. Active substance abuse (including alcohol or drug abuse)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "15", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002128", 
            "org_study_id": "232A", 
            "secondary_id": "GS-93-401"
        }, 
        "intervention": {
            "intervention_name": "Adefovir dipivoxil", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Adefovir", 
                "Adefovir dipivoxil"
            ]
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Antiviral Agents", 
            "Adenine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21205"
                }, 
                "name": "Johns Hopkins Univ"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "8585716", 
            "citation": "Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, Jaffe HS. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1995 Nov;39(11):2401-5. PubMed PMID: 8585716; PubMed Central PMCID: PMC162955."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002128"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1994"
    }, 
    "geocoordinates": {
        "Johns Hopkins Univ": "39.29 -76.612"
    }
}